Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Guidance On ANDA Antibundling Statute Expected In February

Executive Summary

The ANDA bundling and antibundling provisions of the Medicare law will be part of a "short guidance" that FDA expects to issue in February

You may also be interested in...



“Shared Exclusivity” Could Apply To Eight First-Time Generics, FDA Says

At least eight first-time ANDA approvals over the next two years could require a determination of whether 180-day "shared exclusivity" should be awarded, FDA says in a court filing

“Shared Exclusivity” Could Apply To Eight First-Time Generics, FDA Says

At least eight first-time ANDA approvals over the next two years could require a determination of whether 180-day "shared exclusivity" should be awarded, FDA says in a court filing

Paxil Generics On Hold After Court Rejects FDA “Shared Exclusivity” Policy

No more generic versions of GlaxoSmithKline's Paxil will be approved before early March under a court decision rejecting FDA's approach to "shared exclusivity.

Related Content

UsernamePublicRestriction

Register

PS043294

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel